Jiangyan Peoples Hospital

Taizhou, China

Jiangyan Peoples Hospital

Taizhou, China
Time filter
Source Type

Ke J.,Jiangyan Peoples Hospital | Lu K.,Jiangyan Peoples Hospital | Li Y.,Jiangyan Peoples Hospital | Zhu G.,Fudan University
Chinese Journal of Clinical Oncology | Year: 2011

Objective: To evaluate the efficacy and toxicity of the weekly dose of Nedaplatin combined with radiation for esophageal squamous cell carcinoma in elderly patients. Methods: Forty-nine patients were randomly divided into two groups to receive either radiotherapy only (Group 1, 25 cases) or weekly dose of Nedaplatin combined with radiotherapy (Group 2, 24 cases). Patients in both groups received conventional radiotherapy with a total dose of 60 Gy to 66 Gy. In Group 2 30 mg/m 2 of Nedaplatin was administered once a week for six successive weeks starting from the first day of radiotherapy. Results: Among the 24 patients in Group 2, 10 patients achieved CR (41.7%), 11 PR (45.8%), and the reponse rate (CR plus PR) was 87.5%. On the other hand, in Group 1, 4 patients achieved CR (16.0%), 11 PR (44.0%), and the response rate (CR plus PR) was 60.0% (P < 0.05). The occurrence rate of G2/3 toxicity of leukopenia in Group 2 was 54.2%, which was obviously higher than that in Group 1 (P < 0.05). The occurrence rates of G2/3 toxicity of radiation esophagitis between the two groups did not have statistical differences. Conclusion: Weekly dose of Nedaplatin combined with radiotherapy can effectively treat esophageal cancer in elderly patients.

Wang X.J.,Nanjing Medical University | Wang X.J.,China Pharmaceutical University | Zhou L.J.,Jiangyan Peoples Hospital | Zhu X.J.,Nanjing Medical University | And 5 more authors.
Applied Microbiology and Biotechnology | Year: 2014

Diagnosis of many infectious, autoimmune diseases and cancers depends on the detection of specific antibodies against peptide epitope by enzyme-linked immunosorbent assay (ELISA). However, small peptides are difficult to be coated on the plate surfaces. In this study, we selected GnRH as a model hapten to evaluate whether VEGF121 would be suitable as an irrelevant hapten-carrier to develop a universal platform for specific antibodies detection. Firstly, GnRH was fused to the C terminus of VEGF121 and the resultant fusion protein VEGF-GnRH expressed effectively as inclusion bodies in Escherichia coli. Thereafter, VEGF-GnRH was easily purified to near homogeneity with a yield of about 235 mg from 2.1 L induced culture. At last, VEGF-GnRH was used to perform ELISA and western blot, and our results suggested that VEGF-GnRH was capable of detecting anti-GnRH antibodies in sera both qualitatively and quantitatively. Indeed, previous studies of our laboratory had demonstrated that other fusion proteins such as VEGF-Aβ10, VEGF-GRP, VEGF-CETPC, and VEGF-βhCGCTP37 were able to detect their corresponding antibodies specifically. Therefore, VEGF121 may be a suitable irrelevant fusion partner of important diagnostic peptide markers. Our works would shed some light on the development of a universal platform for detection of specific antibodies. © 2014 Springer-Verlag.

Jiang Y.,Nanjing Medical University | Huang X.-E.,Nanjing Medical University | Yan P.-W.,Nanjing Medical University | Cui L.,Jiangyan Peoples Hospital | And 2 more authors.
Asian Pacific Journal of Cancer Prevention | Year: 2010

Aim: To validate the clinical value of a computer assisted program (CAP), (visit website; http://xinenhuang.blog.sohu.com for details) for breast cancer patients who receive postoperative adjuvant chemotherapy. Methods: Patients with histologically confirmed breast cancer after mastectomy who received postoperative chemotherapy in Jiangsu Cancer Hospital and Research Institute were recruited in this study. All eligible patients are divided into three groups: group A, regimen of practical chemotherapy consistent with CAP prediction; group B, partly consistent with CAP prediction; group C, inconsistent with CAP prediction. Overall survival (OS) was compared among groups A, B and C to determine the efficacy of CAP. Results: From November 1992 to July 2007, 310 female breast cancer patients were recruited into this study, with 112, 106 and 89, respectively, in groups A, B, and C. Prognosis of group A was better than both group B and C, with significantly different survival curves between group A and B (p=0.0004) and group A and C (p=0.0046). Conclusion: Validation showed our CAP to provide clinically valuable information on adjuvant chemotherapy for postoperative breast cancer patients.

Zhang Z.-S.,Jiangyan Peoples Hospital | Chen L.-X.,Cancer Hospital of Jiangsu Province
Chinese Journal of Cancer Prevention and Treatment | Year: 2012

OBJECTIVE: To compare the effectiveness and toxicity effect of combine chemotherapy regimen of irinotecan plus carboplatin (IC) and EP regimen in the treatment of SCLC. METHORDS: Seventy-three defined SCLC patients were randomly divided into IC group (n=36) and EP group (n=37). All the patients were given more than two chemotherapy cycles and compare the rate of CR, PR, SD, PD, RR of the two groups. RESULTS: The overall response rate was 58.3% in IC group and 62.2% in EP group. The complete remission was 25.0%(9/36) in IC group and 21.6%(8/37) in EP group. There was no significant difference in the response rate between the two groups (P>0.05). In terms of hematlogic toxicity, neutropenia were more frequent in EP group than those in IC group (P=0.002 5) but there was no significant difference in thrombocytopenia rate (P=0.960 7), leucopenia (P=0.150 0) and anemia rate(P=0.077 5). In terms of toxicity in the gastrointestinal tract there was no significant difference in > III degree diarrhea incidence (P=0.404 7), severe vomiting (P=0.965 0), elevated liver enzymes (P=0.969 6) between the two groups. In nephrotoxicity there was no significant difference in > III degree of hematuria, BUN and creatinine increase rate. Peripheral neuritis, phlebitis, baldness was rarely observed. There was no chemotherapy-related death. CONCLUSION: IC regimen was equally effective and safe for SCLC comparing with EP regimen, we can choose them it for clinical application.

Liu X.,Jiangyan Peoples Hospital | Cui L.,Jiangyan Peoples Hospital | Dong H.,Guizhou Provincial Tumor Hospital
Chinese-German Journal of Clinical Oncology | Year: 2010

Objective: The aim of the study was to investigate the efficacy of three-dimensional conformal radiotherapy (3D-CRT) combined with Temozolomide (TMZ) concurrent chemotherapy in treatment of postoperative cerebral gliomas by prospective randomized controlled trials. Methods: Sixty-two patients with cerebral glioma who had residual tumor were divided into 3D-CRT group (radiotherapy group, n = 31) and 3D-CRT with concurrent chemotherapy group (chemoradiotherapy group, n = 31) prospectively. All patients received a dose of 50-60 Gy/ 25-30 F/ 5-6 weeks by 6 MV-X ray, three-dimensional conformal radiotherapy, 1 f/d, 5 times a week. Chemotherapy regimen was Temozolomide: 75 mg/m2/d, concomitantly with radiotherapy, followed by 150-200 mg/m2/d, 5 days, 28 days per cycle, totally 3-6 cycles. Results: The total response rate was 35.3% (11/31) in radiotherapy group. The response rate was 61.3% (19/31) in chemoradiotherapy group. There was significant difference in curative effect (P = 0.042). There was no significant difference in survival comparison of two groups (P = 0.263). Stratified analysis showed the patients with grade III gliomas of chemoradiotherapy group had better prognosis than ones of radiotherapy group (P = 0.043). Conclusion: The 3D-CRT with concurrent chemotherapy can improve the survival of cerebral gliomas with pathological grade III. © Springer-Verlag Berlin Heidelberg 2010.

Ding L.-D.,Jiangyan Peoples Hospital | Liu Y.,Jiangyan Peoples Hospital
Journal of Clinical Neurology (China) | Year: 2010

Objective: To study the condition of nosocomial infection and its correlative factors in the patients with cerebral vascular disease (CVD). Methods: The clinical manifestation and the results of laboratory tests and imaging examinations of 2108 natients were surveied. The infection rate, mortality, infection focus and the relative factors were calculated and analysed. Results: There were 726 CVD patients (34. 4%) with nosocomial infection. The mertality of CVD patients with nosocomial infection (152 cases, 17.2%) was significantly higher than those without nosocomial infection (112 cases, 8. 1%, P < 0.01). Nosocomial infection mostly happened in respiratory tract (64.2%) and urinary tract (21.1%). Nosocomial infection rate of the patient with elder age, long time of hospitalization, intracerebral hemorrhage (ICH), disturbance of consciousness, invasive treatment and hyperglycemia, were significantly higher than those patients with younger age, short time ol hospitalization, cerebral infarction (CI), and without disturbance of consciousness, invasive treatment and hyperglycemia (all P< 0.01). Conclusions: CVD patients have high rate of nosocomial inlection, which cause the growing of patients mortality. Elder age, long time of hospitalization, ICH, disturbance ot consciousness, invasive treatment and hyperglycemia are the common correlative factors in the CVD.

Loading Jiangyan Peoples Hospital collaborators
Loading Jiangyan Peoples Hospital collaborators